Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 November 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 192 pages)

 

Export 70 results:
Author Title [ Type(Asc)] Year
Filters: Author is Leufkens, H. G.  [Clear All Filters]
Journal Article
S. Pouwels, de Boer, A., Javaid, M. K., Hilton-Jones, D., Verschuuren, J., Cooper, C., Leufkens, H. G., and de Vries, F., Fracture rate in patients with myasthenia gravis: the general practice research database, Osteoporos Int, vol. 24, pp. 467-76, 2013.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
T. P. van Staa, Dennison, E. M., Leufkens, H. G., and Cooper, C., Epidemiology of fractures in England and Wales, Bone, vol. 29, pp. 517-22, 2001.
C. Cooper, Dennison, E. M., Leufkens, H. G., Bishop, N., and van Staa, T. P., Epidemiology of childhood fractures in Britain: a study using the general practice research database, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?, J Intern Med, vol. 264, pp. 481-92, 2008.
T. P. van Staa, Leufkens, H. G., and Cooper, C., Does a fracture at one site predict later fractures at other sites? A British cohort study, Osteoporos Int, vol. 13, pp. 624-9, 2002.
B. M. Verdel, Souverein, P. C., Egberts, A. C., and Leufkens, H. G., Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure, Ann Pharmacother, vol. 40, pp. 1040-6, 2006.
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example, PLoS Med, vol. 6, p. e1000194, 2009.
H. A. van den Ham, Klungel, O. H., Singer, D. E., Leufkens, H. G., and van Staa, T. P., Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database, J Am Coll Cardiol, vol. 66, pp. 1851-9, 2015.
T. P. van Staa, Geusens, P., Bijlsma, J. W., Leufkens, H. G., and Cooper, C., Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
T. P. van Staa, Cooper, C., Leufkens, H. G., and Bishop, N., Children and the risk of fractures caused by oral corticosteroids, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
E. Setakis, Leufkens, H. G., and van Staa, T. P., Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
A. Lalmohamed, Bazelier, M. T., van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., de Boer, A., and de Vries, F., Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
J. H. Driessen, Henry, R. M., van Onzenoort, H. A., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G., and de Vries, F., Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
T. P. van Staa, Bishop, N., Leufkens, H. G., and Cooper, C., Are inhaled corticosteroids associated with an increased risk of fracture in children?, Osteoporos Int, vol. 15, pp. 785-91, 2004.
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
E. M. van de Garde, Souverein, P. C., Hak, E., Deneer, V. H., van den Bosch, J. M., and Leufkens, H. G., Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes, J Hypertens, vol. 25, pp. 235-9, 2007.
T. P. van Staa, Travis, S., Leufkens, H. G., and Logan, R. F., 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study, Gastroenterology, vol. 126, pp. 1733-9, 2004.
T. P. van Staa, Card, T., Logan, R. F., and Leufkens, H. G., 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study, Gut, vol. 54, pp. 1573-8, 2005.
[Page last reviewed 4 November 2019]